Hope Therapeutics, a subsidiary of NRx Pharmaceuticals, announced a partnership with French MedTech company Emobot Health to integrate Emobot’s AI‑powered “Depression Thermometer” into its interventional psychiatry clinics. The collaboration will deploy the passive monitoring platform across Hope’s expanding network, giving clinicians real‑time data on patients’ emotional state, sleep, and activity levels.
The partnership is a strategic move that fits NRx’s broader plan to build a nationwide network of interventional psychiatry clinics and leverage technology to improve care for treatment‑resistant depression. By providing continuous, objective monitoring, the tool addresses a critical gap in TRD care: the high relapse rate—about 50% within 6‑12 months—that often goes undetected between clinic visits. Earlier intervention enabled by the platform is expected to improve treatment outcomes and create new revenue opportunities for the clinic network.
Emobot’s “Depression Thermometer” is a passive, AI‑driven system that collects smartphone data to assess emotional states, sleep, and activity. In preliminary studies, the device showed strong concordance with established clinical scales, achieving a correlation of 0.89 with the MADRS and 0.83 with the PHQ‑9. The technology moves away from burdensome questionnaires and offers clinicians a continuous, objective biomarker stream.
The partnership could enhance Hope’s clinic revenue streams by improving patient outcomes and enabling earlier intervention for relapse. NRx recently reported positive Q4 2025 results, with reduced operating losses and R&D expenses, and analysts predict the company will become profitable in 2026 with significant revenue growth. The addition of Emobot’s platform strengthens the value proposition of the clinic network and supports the company’s trajectory toward profitability.
Jonathan Javitt, founder and CEO of Hope Therapeutics, said, “Precision medicine requires real‑time data to be effective. Emobot’s passive, multimodal AI provides us with a continuous stream of objective biomarkers.” The partnership underscores NRx’s commitment to integrating digital health solutions into its treatment model and aligns with its pipeline of novel therapies for suicidal depression and other central nervous system disorders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.